 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LORAZEPAM increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LORAZEPAM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse reactions to benzodiazepines, including CNS effects and respiratory depression, are dose dependent, with more severe effects [0m
[31moccurring with high doses. In a sample of about [0m[1;31m3500[0m[31m patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation [0m[1;31m([0m[1;31m15.9[0m[31m%[0m[1;31m)[0m[31m, followed by dizziness [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m, weakness [0m[1;31m([0m[1;31m4.2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mand unsteadiness [0m[1;31m([0m[1;31m3.4[0m[31m%[0m[1;31m)[0m[31m. The incidence of sedation and unsteadiness increased with age. LORAZEPAM: adverse_reactions: Other adverse reactions to benzodiazepines, including lorazepam are fatigue, [0m
[31mdrowsiness, amnesia, memory impairment, confusion, disorientation, depression, unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt, ataxia, asthenia, extrapyramidal symptoms, [0m
[31mconvulsions/seizures, tremor, vertigo, eye function/visual disturbance [0m[1;31m([0m[31mincluding diplopia and blurred vision[0m[1;31m)[0m[31m, dysarthria/slurred speech, change in libido, impotence, decreased orgasm; headache, [0m
[31mcoma; respiratory depression, apnea, worsening of sleep apnea, worsening of obstructive pulmonary disease; gastrointestinal symptoms including nausea, change in appetite, constipation, jaundice, [0m
[31mincrease in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; hypersensitivity reactions, anaphylactoid reactions; dermatological symptoms, allergic skin reactions, [0m
[31malopecia; syndrome of inappropriate antidiuretic LORAZEPAM: adverse_reactions: hormone [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m, hyponatremia; thrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic [0m
[31mmanifestations. Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. Small decreases[0m
[31min blood pressure and hypotension may occur but are usually not clinically significant, probably being related to the relief of anxiety produced by lorazepam. To report SUSPECTED ADVERSE REACTIONS, [0m
[31mcontact Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: precautions: Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lorazepam during pregnancy [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy[0m
[1;31m)[0m[31m. Nursing Instruct patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients using lorazepam to monitor infants for excessive [0m
[31msedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs [0m[1;31m([0m[31msee PRECAUTIONS: Nursing Mothers [0m[1;31m)[0m[31m. Essential Laboratory Tests Some patients on lorazepam have [0m
[31mdeveloped leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are recommended for patients on long-term therapy. Drug [0m
[31mInteractions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. [0m
[31mBenzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. LORAZEPAM: precautions: When benzodiazepines and opioids are combined, the potential for benzodiazepines to [0m
[31msignificantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression [0m
[31mand sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, [0m
[31msedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. Concomitant use of clozapine and lorazepam may produce marked [0m
[31msedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced [0m
[31mclearance of lorazepam. LORAZEPAM: precautions: Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam with probenecid may [0m
[31mresult in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% when coadministered [0m
[31mwith probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the sedative effects of [0m
[31mbenzodiazepines, including lorazepam. Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an [0m[1;31m18[0m[31m-month study with lorazepam. No studies regarding mutagenesis [0m
[31mhave been performed. LORAZEPAM: pregnancy: Pregnancy Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including [0m
[31mlorazepam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m961[0m[31m-[0m[1;31m2388[0m[31m or visiting online at [0m
[4;31mhttps://womensmentalhealth.org/pregnancyregistry/.[0m[31m Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal [0m
[31mwithdrawal [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and Clinical Considerations [0m[1;31m)[0m[31m. Available data from published observational studies of pregnant women exposed to benzodiazepines do [0m
[31mnot report a clear association with benzodiazepines and major birth defects [0m[1;31m([0m[31msee Data[0m[1;31m)[0m[31m . The background risk of major birth defects and miscarriage for the indicated population is unknown. All [0m
[31mpregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. LORAZEPAM: pregnancy: general population, the estimated risk of major birth defects and of miscarriage [0m
[31min clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory [0m
[31mdepression, hypotonia and sedation in neonates. Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor [0m
[31mneonates exposed to lorazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome [0m[1;31m)[0m[31m. Data Human Data Published data [0m
[31mfrom observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. LORAZEPAM: pregnancy: Although early studies [0m
[31mreported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of more recent case-control and cohort [0m
[31mstudies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. Animal Data Reproductive [0m
[31mstudies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies [0m[1;31m([0m[31mreduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull, and [0m
[31mmicrophthalmia[0m[1;31m)[0m[31m were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the concurrent control group, they have been reported to occur [0m
[31mrandomly in historical controls. At doses of [0m[1;31m40[0m[31m mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses. LORAZEPAM: precautions: [0m
[31mNursing Mothers Risk Summary Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The [0m
[31meffects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for lorazepam and any potential [0m
[31madverse effects on the breastfed infant from lorazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to lorazepam through breast milk should be monitored for [0m
[31msedation, poor feeding and poor weight gain. Geriatric Use Clinical studies of lorazepam generally were not adequate to determine whether subjects aged [0m[1;31m65[0m[31m and over respond differently than younger [0m
[31msubjects; however, the incidence of sedation and unsteadiness was observed to increase with age [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Age does not appear to have a significant effect on lorazepam kinetics [0m[1;31m([0m[31msee [0m
[31mCLINICAL PHARMACOLOGY [0m[1;31m)[0m[31m. LORAZEPAM: precautions: Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered. Greater sensitivity[0m
[1;31m([0m[31me.g., sedation[0m[1;31m)[0m[31m of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower doses may be sufficient in these patients [0m[1;31m([0m[31msee DOSAGE [0m
[31mAND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: spl_medguide_table: [0m[1;31m<[0m[31m/[0m[31mcontent[0m[31m>There is a risk of abuse, misuse, and addiction with benzodiazepines including lorazepam tablets which can lead to overdose and serious side effects [0m
[31mincluding coma and death. <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Serious side effects including coma and death have happened in people who have abused or[0m
[31mmisused benzodiazepines, including lorazepam tablets.<[0m[31m/[0m[31mcontent[0m[31m> These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. [0m
[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side [0m
[31meffects.<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>You can develop an addiction even if you take lorazepam tablets exactly as prescribed by your healthcare provider. [0m
[31mLORAZEPAM: spl_medguide_table: content><[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Take lorazepam tablets exactly as your healthcare provider [0m
[31mprescribed.<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>Do not share your lorazepam tablets with other people.<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>Keep lorazepam tablets in a safe place and [0m
[31maway from children.<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Physical dependence and withdrawal reactions. <[0m[31m/[0m[31mcontent[0m[31m>Lorazepam tablets can cause physical [0m
[31mdependence and withdrawal reactions. <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not suddenly stop taking lorazepam tablets. LORAZEPAM: spl_medguide_table:[0m
[31mcontent> Stopping lorazepam tablets suddenly can cause serious and life-threatening side effects, including, unusual movements, responses or expressions, seizures, sudden and severe mental or nervous [0m
[31msystem changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms. LORAZEPAM: spl_medguide_table: [0m
[31mcontent><[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than [0m[1;31m12[0m[31m months,<[0m[31m/[0m[31mcontent[0m[31m> [0m
[31mincluding anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or [0m
[31mprickling feeling in your hands, arms, legs or feet, and ringing in your ears.<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>Physical dependence is not the same as drug addiction. Your healthcare provider [0m
[31mcan tell you more about the differences between physical dependence and drug addiction.<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>Do not take more lorazepam tablets than prescribed or take lorazepam [0m
[31mtablets for longer than prescribed. LORAZEPAM: spl_medguide_table: item><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>What [0m
[31mare lorazepam tablets?<[0m[31m/[0m[31mcontent[0m[31m>   <[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>Lorazepam tablets are a prescription medicine used: <list [0m
[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>to treat anxiety disorders<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>for the short-term relief of the symptoms of anxiety or anxiety that can happen [0m
[31mwith symptoms of depression<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Lorazepam tablets are a federal controlled substance [0m[1;31m([0m[31mCIV[0m[1;31m)[0m[31m because it contains lorazepam that can be abused[0m
[31mor lead to dependence.<[0m[31m/[0m[31mcontent[0m[1;31m>[0m[31m Keep lorazepam tablets in a safe place to prevent misuse and abuse.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: warnings: WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including lorazepam, and opioids may result in profound sedation, respiratory [0m
[31mdepression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Observational studies have [0m
[31mdemonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe lorazepam [0m
[31mconcomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. [0m
[31mIn patients already receiving an opioid analgesic, prescribe a lower initial dose of lorazepam than indicated in the absence of an opioid and titrate based on clinical response. LORAZEPAM: warnings: [0m
[31mIf an opioid is initiated in a patient already taking lorazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the [0m
[31mrisks of respiratory depression and sedation when lorazepam is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been[0m
[31mdetermined [0m[1;31m([0m[31msee PRECAUTIONS: Drug Interactions [0m[1;31m)[0m[31m. Abuse, Misuse, and Addiction The use of benzodiazepines, including lorazepam, exposes users to the risks of abuse, misuse, and addiction, which can [0m
[31mlead to overdose or death. LORAZEPAM: warnings: Abuse and misuse of benzodiazepines often [0m[1;31m([0m[31mbut not always[0m[1;31m)[0m[31m involve the use of doses greater than the maximum recommended dosage and commonly involve [0m
[31mconcomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or [0m
[31mdeath [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Abuse [0m[1;31m)[0m[31m. Before prescribing lorazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [0m[1;31m([0m[31me.g., using a standardized screening [0m
[31mtool[0m[1;31m)[0m[31m. Use of lorazepam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of lorazepam along with monitoring for signs and symptoms of abuse, misuse, [0m
[31mand addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction [0m[1;31m([0m[31me.g.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: drug_interactions: Drug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites [0m
[31min the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for [0m
[31mbenzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for [0m
[31mrespiratory depression and sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, [0m
[31mantipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. LORAZEPAM: drug_interactions: Concomitant use of [0m
[31mclozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in [0m
[31mincreased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam [0m
[31mwith probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% [0m
[31mwhen coadministered with probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the [0m
[31msedative effects of benzodiazepines, including lorazepam.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: pharm_class_cs         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: spl_id         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. • The use of benzodiazepines, [0m
[31mincluding lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other [0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. LORAZEPAM: boxed_warning: Before prescribing lorazepam and throughout [0m
[31mtreatment, assess each patient’s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. • The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical [0m
[31mdependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may [0m
[31mprecipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage [0m[1;31m([0m[31m DOSAGE AND [0m
[31mADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: dosage_and_administration: DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy [0m
[31mshould be individualized according to patient response. To facilitate this, [0m[1;31m0.5[0m[31m mg, [0m[1;31m1[0m[31m mg, and [0m[1;31m2[0m[31m mg tablets are available. The usual range is [0m[1;31m2[0m[31m to [0m[1;31m6[0m[31m mg/day given in divided doses, the largest dose [0m
[31mbeing taken before bedtime, but the daily dosage may vary from [0m[1;31m1[0m[31m to [0m[1;31m10[0m[31m mg/day. For anxiety, most patients require an initial dose of [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m mg/day given two times a day or three times a day. For [0m
[31minsomnia due to anxiety or transient situational stress, a single daily dose of [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m mg may be given, usually at bedtime. For elderly or debilitated patients, an initial dosage of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mg/day in [0m
[31mdivided doses is recommended, to be adjusted as needed and tolerated. LORAZEPAM: dosage_and_administration: The dosage of lorazepam tablets should be increased gradually when needed to help avoid [0m
[31madverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of [0m
[31mwithdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the [0m
[31mprevious tapered dosage level. Subsequently decrease the dosage more slowly [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of bleeding. The adverse reactions and drug interactions sections of the [0m
[32mlabel mention various effects and interactions, but bleeding risk is not specifically mentioned.[0m

[32mSOURCE: LORAZEPAM label[0m
[32mEXTRACT_START_END: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse[0m[32m...[0m[32m and autonomic manifestations.[0m
*[1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the LORAZEPAM label does not indicate [0m
[34mthat lorazepam increases or decreases the risk of bleeding. The adverse reactions and drug interactions sections of the label mention various effects and interactions, but bleeding risk is not [0m
[34mspecifically mentioned.[0m

[34mSOURCE: LORAZEPAM label[0m
[34mEXTRACT_START_END: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse[0m[34m...[0m[34m and autonomic manifestations.[0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of bleeding. The adverse reactions and drug [0m
[32minteractions sections of the label mention various effects and interactions, but bleeding risk is not specifically mentioned."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The risk of bleeding is not specifically mentioned in the LORAZEPAM label, indicating that there is no verified causal relationship between LORAZEPAM and an increased or decreased risk [0m
[32mof bleeding according to the FDA label data."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LORAZEPAM increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of bleeding. The adverse reactions and drug [0m
[34minteractions sections of the label mention various effects and interactions, but bleeding risk is not specifically mentioned."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The risk of bleeding is not specifically mentioned in the LORAZEPAM label, indicating that there is no verified causal relationship between LORAZEPAM and an increased or decreased risk [0m
[34mof bleeding according to the FDA label data."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LORAZEPAM increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether LORAZEPAM increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of bleeding. The adverse reactions and drug [0m
[31minteractions sections of the label mention various effects and interactions, but bleeding risk is not specifically mentioned.[0m
[31m        -----[0m
[31m        Final answer: The risk of bleeding is not specifically mentioned in the LORAZEPAM label, indicating that there is no verified causal relationship between LORAZEPAM and an increased or [0m
[31mdecreased risk of bleeding according to the FDA label data.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe question was whether LORAZEPAM increases or decreases the risk of bleeding. I consulted FDAHandler, and the response indicated that the LORAZEPAM label does not mention an increased or decreased [0m
[32mrisk of bleeding in the adverse reactions and drug interactions sections. Therefore, there is no verified causal relationship between LORAZEPAM and an increased or decreased risk of bleeding according[0m
[32mto the FDA label data.[0m
